In addition, lapatinib, a dual tyrosine kinase inhibitor of EGFR and ERBB2, induced autophagic cell death in breast cancer cells overexpressing ERBB240, human hepatoma cells41, and acute myeloblastic leukemia42. Here, ERBB2 is linked to breast carcinoma.